Pathological and therapeutic roles of bioactive peptide trefoil factor 3 in diverse diseases: recent progress and perspective.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
17 01 2022
17 01 2022
Historique:
received:
27
07
2021
accepted:
30
12
2021
revised:
23
12
2021
entrez:
18
1
2022
pubmed:
19
1
2022
medline:
9
4
2022
Statut:
epublish
Résumé
Trefoil factor 3 (TFF3) is the last small-molecule peptide found in the trefoil factor family, which is mainly secreted by intestinal goblet cells and exerts mucosal repair effect in the gastrointestinal tract. Emerging evidence indicated that the TFF3 expression profile and biological effects changed significantly in pathological states such as cancer, colitis, gastric ulcer, diabetes mellitus, non-alcoholic fatty liver disease, and nervous system disease. More importantly, mucosal protection would no longer be the only effect of TFF3, it gradually exhibits carcinogenic activity and potential regulatory effect of nervous and endocrine systems, but the inner mechanisms remain unclear. Understanding the molecular function of TFF3 in specific diseases might provide a new insight for the clinical development of novel therapeutic strategies. This review provides an up-to-date overview of the pathological effects of TFF3 in different disease and discusses the binding proteins, signaling pathways, and clinical application.
Identifiants
pubmed: 35039476
doi: 10.1038/s41419-022-04504-6
pii: 10.1038/s41419-022-04504-6
pmc: PMC8763889
doi:
Substances chimiques
TFF3 protein, human
0
Trefoil Factor-3
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
62Subventions
Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 81830113
Informations de copyright
© 2022. The Author(s).
Références
Muskett F, May F, Westley B, Feeney J. Solution structure of the disulfide-linked dimer of human intestinal trefoil factor (TFF3): the intermolecular orientation and interactions are markedly different from those of other dimeric trefoil proteins. Biochemistry. 2003;42:15139–47.
pubmed: 14690424
doi: 10.1021/bi030182k
Prest S, May F, Westley B. The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. FASEB J. 2002;16:592–4.
pubmed: 11919164
doi: 10.1096/fj.01-0498fje
Poulsen S, Kissow H, Hare K, Hartmann B, Thim L. Luminal and parenteral TFF2 and TFF3 dimer and monomer in two models of experimental colitis in the rat. Regulatory Pept. 2005;126:163–71.
doi: 10.1016/j.regpep.2004.09.007
Kinoshita K, Taupin D, Itoh H, Podolsky D. Distinct pathways of cell migration and antiapoptotic response to epithelial injury: structure-function analysis of human intestinal trefoil factor. Mol Cell Biol. 2000;20:4680–90.
pubmed: 10848594
pmcid: 85884
doi: 10.1128/MCB.20.13.4680-4690.2000
Bernstein H, Dobrowolny H, Trübner K, Steiner J, Bogerts B, Hoffmann W. Differential regional and cellular distribution of TFF3 peptide in the human brain. Amino Acids. 2015;47:1053–63.
pubmed: 25691144
doi: 10.1007/s00726-015-1938-9
Srivatsa G, Giraud A, Ulaganathan M, Yeomans N, Dow C, Nicoll A. Biliary epithelial trefoil peptide expression is increased in biliary diseases. Histopathology. 2002;40:261–8.
pubmed: 11895492
doi: 10.1046/j.1365-2559.2002.01347.x
Rinnert M, Hinz M, Buhtz P, Reiher F, Lessel W, Hoffmann W. Synthesis and localization of trefoil factor family (TFF) peptides in the human urinary tract and TFF2 excretion into the urine. Cell Tissue Res. 2010;339:639–47.
pubmed: 20063012
doi: 10.1007/s00441-009-0913-8
Jackerott M, Lee Y, Møllgård K, Kofod H, Jensen J, Rohleder S, et al. Trefoil factors are expressed in human and rat endocrine pancreas: differential regulation by growth hormone. Endocrinology. 2006;147:5752–9.
pubmed: 16973727
doi: 10.1210/en.2006-0601
Poulsom R, Hanby A, Lalani E, Hauser F, Hoffmann W, Stamp G. Intestinal trefoil factor (TFF 3) and pS2 (TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium. J Pathol. 1997;183:30–38.
pubmed: 9370944
doi: 10.1002/(SICI)1096-9896(199709)183:1<30::AID-PATH1085>3.0.CO;2-K
Wiede A, Jagla W, Welte T, Köhnlein T, Busk H, Hoffmann W. Localization of TFF3, a new mucus-associated peptide of the human respiratory tract. Am J Respir. Crit Care Med. 1999;159:1330–5.
pubmed: 10194185
doi: 10.1164/ajrccm.159.4.9804149
Langer G, Jagla W, Behrens-Baumann W, Walter S, Hoffmann W. Secretory peptides TFF1 and TFF3 synthesized in human conjunctival goblet cells. Invest. Ophthalmol Vis Sci. 1999;40:2220–4.
pubmed: 10476786
Cook G, Familari M, Thim L, Giraud A. The trefoil peptides TFF2 and TFF3 are expressed in rat lymphoid tissues and participate in the immune response. FEBS Lett. 1999;456:155–9.
pubmed: 10452549
doi: 10.1016/S0014-5793(99)00940-0
Taupin D, Podolsky D. Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol. 2003;4:721–32.
pubmed: 14506475
doi: 10.1038/nrm1203
Hoffmann W. Trefoil factor family (TFF) peptides and chemokine receptors: a promising relationship. J Med. Chem. 2009;52:6505–10.
pubmed: 19888754
doi: 10.1021/jm9008136
Mashimo H, Wu D, Podolsky D, Fishman M. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 1996;274:262–5.
pubmed: 8824194
doi: 10.1126/science.274.5285.262
Beck P, Wong J, Li Y, Swaminathan S, Xavier R, Devaney K, et al. Chemotherapy- and radiotherapy-induced intestinal damage is regulated by intestinal trefoil factor. Gastroenterology. 2004;126:796–808.
pubmed: 14988834
doi: 10.1053/j.gastro.2003.12.004
Paulsen F, Woon C, Varoga D, Jansen A, Garreis F, Jäger K, et al. Intestinal trefoil factor/TFF3 promotes re-epithelialization of corneal wounds. J Biol Chem. 2008;283:13418–27.
pubmed: 18326859
pmcid: 2442345
doi: 10.1074/jbc.M800177200
Shah A, Leidinger P, Keller A, Wendschlag A, Backes C, Baus-Loncar M, et al. The intestinal factor Tff3 and a miRNA network regulate murine caloric metabolism. RNA Biol. 2011;8:77–81.
pubmed: 21289491
doi: 10.4161/rna.8.1.13687
Wu X, Zheng H, Yang R, Luan X, Zhang L, Jin Q, et al. Mouse trefoil factor 3 ameliorated high-fat-diet-induced hepatic steatosis via increasing peroxisome proliferator-activated receptor-α-mediated fatty acid oxidation. Am J Physiol Endocrinol Metab. 2019;317:E436–E445.
pubmed: 31211621
doi: 10.1152/ajpendo.00454.2018
Kozina N, Mihaljević Z, Lončar M, Mihalj M, Mišir M, Radmilović M, et al. Tff3Impact of high salt diet on cerebral vascular function and stroke in C57BL/6N knockout and WT (C57BL/6N) control mice. Int J Mol Sci. 2019;20:5188.
Liu S, Roberts D, Zhang B, Ren Y, Zhang L, Wu Y. Trefoil factor 3 as an endocrine neuroprotective factor from the liver in experimental cerebral ischemia/reperfusion injury. PLoS ONE. 2013;8:e77732.
pubmed: 24204940
pmcid: 3799633
doi: 10.1371/journal.pone.0077732
Mohammadi-Shemirani P, Sjaarda J, Gerstein H, Treleaven D, Walsh M, Mann J, et al. A mendelian randomization-based approach to identify early and sensitive diagnostic biomarkers of disease. Clin Chem. 2019;65:427–36.
pubmed: 30337280
doi: 10.1373/clinchem.2018.291104
Du T, Luo H, Qin H, Wang F, Wang Q, Xiang Y, et al. Circulating serum trefoil factor 3 (TFF3) is dramatically increased in chronic kidney disease. PloS one. 2013;8:e80271.
pubmed: 24282531
pmcid: 3840008
doi: 10.1371/journal.pone.0080271
Astor B, Köttgen A, Hwang S, Bhavsar N, Fox C, Coresh J. Trefoil factor 3 predicts incident chronic kidney disease: a case-control study nested within the Atherosclerosis Risk in Communities (ARIC) study. Am J Nephrol. 2011;34:291–7.
pubmed: 21829008
pmcid: 3169359
doi: 10.1159/000330699
Brott D, Furlong S, Adler S, Hainer J, Arani R, Pinches M, et al. Characterization of renal biomarkers for use in clinical trials: effect of preanalytical processing and qualification using samples from subjects with diabetes. Drug Des, Dev Ther. 2015;9:3191–8.
doi: 10.2147/DDDT.S78792
Roa GJB, Tortolero GS, Gonzalez JE. Trefoil factor 3 (TFF3) expression is regulated by insulin and glucose. J Health Sci. 2013; https://doi.org/10.17532/jhsci.2013.26 .
Tran C, Familari M, Parker L, Whitehead R, Giraud A. Short-chain fatty acids inhibit intestinal trefoil factor gene expression in colon cancer cells. Am J Physiol. 1998;275:G85–94.
pubmed: 9655688
Xue Y, Shen L, Cui Y, Zhang H, Chen Q, Cui A, et al. Tff3, as a novel peptide, regulates hepatic glucose metabolism. PLoS ONE. 2013;8:e75240.
pubmed: 24086476
pmcid: 3781022
doi: 10.1371/journal.pone.0075240
Ge H, Gardner J, Wu X, Rulifson I, Wang J, Xiong Y, et al. Trefoil factor 3 (TFF3) is regulated by food intake, improves glucose tolerance and induces mucinous metaplasia. PLoS ONE. 2015;10:e0126924.
pubmed: 26083576
pmcid: 4471263
doi: 10.1371/journal.pone.0126924
Zhou F, Zhou J, Wang W, Zhang X, Ji Y, Zhang P, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis. Hepatol (Baltim, Md). 2019;70:1119–33.
doi: 10.1002/hep.30702
Guillén N, Navarro M, Arnal C, Noone E, Arbonés-Mainar J, Acín S, et al. Microarray analysis of hepatic gene expression identifies new genes involved in steatotic liver. Physiol Genomics. 2009;37:187–98.
pubmed: 19258494
pmcid: 2685506
doi: 10.1152/physiolgenomics.90339.2008
Brown A, Olver W, Donnelly C, May M, Naggert J, Shaffer D, et al. Searching QTL by gene expression: analysis of diabesity. BMC Genet. 2005;6:12.
pubmed: 15760467
pmcid: 555939
doi: 10.1186/1471-2156-6-12
Bujak M, Bujak I, Sobočanec S, Mihalj M, Novak S, Ćosić A, et al. Trefoil factor 3 deficiency affects liver lipid metabolism. Cell Physiol Biochem. 2018;47:827–41.
pubmed: 29807366
doi: 10.1159/000490039
Šešelja K, Bazina I, Welss J, Schicht M, Paulsen F, Bijelić N, et al. Effect of Tff3 deficiency and ER stress in the liver. Int J Mol Sci. 2019;20:4389.
Jagla W, Wiede A, Dietzmann K, Rutkowski K, Hoffmann W. Co-localization of TFF3 peptide and oxytocin in the human hypothalamus. FASEB J. 2000;14:1126–31.
pubmed: 10834934
doi: 10.1096/fasebj.14.9.1126
Probst J, Zetzsche T, Weber M, Theilemann P, Skutella T, Landgraf R, et al. Human intestinal trefoil factor is expressed in human hypothalamus and pituitary: evidence for a novel neuropeptide. FASEB J. 1996;10:1518–23.
pubmed: 8940297
doi: 10.1096/fasebj.10.13.8940297
Paterson R, Bartlett J, Blennow K, Fox N, Shaw L, Trojanowski J, et al. Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. Transl Psychiatry. 2014;4:e419.
pubmed: 25072324
pmcid: 4119225
doi: 10.1038/tp.2014.58
Zou J, Chen Z, Liang C, Fu Y, Wei X, Lu J, et al. Trefoil factor 3, cholinesterase and homocysteine: potential predictors for Parkinson’s disease dementia and vascular Parkinsonism dementia in advanced stage. Aging Dis. 2018;9:51–65.
pubmed: 29392081
pmcid: 5772858
doi: 10.14336/AD.2017.0416
Lubka M, Müller M, Baus-Loncar M, Hinz M, Blaschke K, Hoffmann W, et al. Lack of Tff3 peptide results in hearing impairment and accelerated presbyacusis. Cell Physiol Biochem. 2008;21:437–44.
pubmed: 18453751
doi: 10.1159/000129636
Lubka-Pathak M, Shah A, Gallozzi M, Müller M, Zimmermann U, Löwenheim H, et al. Altered expression of securin (Pttg1) and serpina3n in the auditory system of hearing-impaired Tff3-deficient mice. Cell Mol life Sci. 2011;68:2739–49.
pubmed: 21076990
doi: 10.1007/s00018-010-0586-1
Shi H, Zhu W, Liu J, Luo Y, Si J, Wang S, et al. PI3K/Akt signaling pathway in the basolateral amygdala mediates the rapid antidepressant-like effects of trefoil factor 3. Neuropsychopharmacology. 2012;37:2671–83.
pubmed: 22828749
pmcid: 3473333
doi: 10.1038/npp.2012.131
Schwarzberg H, Kalbacher H, Hoffmann W. Differential behavioral effects of TFF peptides: injections of synthetic TFF3 into the rat amygdala. Pharmacol Biochem Behav. 1999;62:173–8.
pubmed: 9972861
doi: 10.1016/S0091-3057(98)00137-3
Shi H, Yin X, Song L, Guo Q, Luo X. Neuropeptide trefoil factor 3 improves learning and retention of novel object recognition memory in mice. Behavioural Brain Res. 2012;227:265–9.
doi: 10.1016/j.bbr.2011.10.051
Li J, Luo Y, Zhang R, Shi H, Zhu W, Shi J. Neuropeptide trefoil factor 3 reverses depressive-like behaviors by activation of BDNF-ERK-CREB signaling in olfactory bulbectomized rats. Int J Mol Sci. 2015;16:28386–28400.
pubmed: 26633367
pmcid: 4691052
doi: 10.3390/ijms161226105
Arnold P, Rickert U, Helmers A, Spreu J, Schneppenheim J, Lucius R. Trefoil factor 3 shows anti-inflammatory effects on activated microglia. Cell tissue Res. 2016;365:3–11.
pubmed: 26899249
doi: 10.1007/s00441-016-2370-5
Luo Y, Han H, Shao J, Gao Y, Yin X, Zhu W, et al. mTOR signalling in the nucleus accumbens shell is critical for augmented effect of TFF3 on behavioural response to cocaine. Sci Rep. 2016;6:27895.
pubmed: 27282818
pmcid: 4901260
doi: 10.1038/srep27895
Wu P, Shi H, Luo Y, Zhang R, Li J, Shi J, et al. Neuropeptide trefoil factor 3 attenuates naloxone-precipitated withdrawal in morphine-dependent mice. Psychopharmacology. 2014;231:4659–68.
pubmed: 24825609
doi: 10.1007/s00213-014-3615-1
Lanas A, Chan F. Peptic ulcer disease. Lancet (Lond, Engl). 2017;390:613–24.
doi: 10.1016/S0140-6736(16)32404-7
Longman R, Douthwaite J, Sylvester P, Poulsom R, Corfield A, Thomas M, et al. Coordinated localisation of mucins and trefoil peptides in the ulcer associated cell lineage and the gastrointestinal mucosa. Gut. 2000;47:792–800.
pubmed: 11076877
pmcid: 1728152
doi: 10.1136/gut.47.6.792
Kouznetsova I, Kalinski T, Meyer F, Hoffmann W. Self-renewal of the human gastric epithelium: new insights from expression profiling using laser microdissection. Mol Biosyst. 2011;7:1105–12.
pubmed: 21240392
doi: 10.1039/c0mb00233j
Kouznetsova I, Peitz U, Vieth M, Meyer F, Vestergaard E, Malfertheiner P, et al. A gradient of TFF3 (trefoil factor family 3) peptide synthesis within the normal human gastric mucosa. Cell Tissue Res. 2004;316:155–65.
pubmed: 14968359
doi: 10.1007/s00441-004-0854-1
Alison M, Chinery R, Poulsom R, Ashwood P, Longcroft J, Wright N. Experimental ulceration leads to sequential expression of spasmolytic polypeptide, intestinal trefoil factor, epidermal growth factor and transforming growth factor alpha mRNAs in rat stomach. J Pathol. 1995;175:405–14.
pubmed: 7790995
doi: 10.1002/path.1711750408
Taupin D, Pedersen J, Familari M, Cook G, Yeomans N, Giraud A. Augmented intestinal trefoil factor (TFF3) and loss of pS2 (TFF1) expression precedes metaplastic differentiation of gastric epithelium. Lab Invest. 2001;81:397–408.
pubmed: 11310832
doi: 10.1038/labinvest.3780247
Chinery R, Playford R. Combined intestinal trefoil factor and epidermal growth factor is prophylactic against indomethacin-induced gastric damage in the rat. Clin Sci. 1995;88:401–3.
doi: 10.1042/cs0880401
Babyatsky M, deBeaumont M, Thim L, Podolsky D. Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats. Gastroenterology. 1996;110:489–97.
pubmed: 8566596
doi: 10.1053/gast.1996.v110.pm8566596
Dignass A, Lynch-Devaney K, Kindon H, Thim L, Podolsky D. Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway. J Clin Invest. 1994;94:376–83.
pubmed: 8040278
pmcid: 296319
doi: 10.1172/JCI117332
Huang Y, Wang M, Yang Z, Ren Y, Zhang W, Sun Z, et al. viaPretreatment with intestinal trefoil factor alleviates stress-induced gastric mucosal damage Akt signaling. World J Gastroenterol. 2020;26:7619–32.
pubmed: 33505140
pmcid: 7789054
doi: 10.3748/wjg.v26.i48.7619
Yu H, He Y, Zhang X, Peng Z, Yang Y, Zhu R, et al. The rat IgGFcγBP and Muc2 C-terminal domains and TFF3 in two intestinal mucus layers bind together by covalent interaction. PLoS ONE. 2011;6:e20334.
pubmed: 21629776
pmcid: 3100329
doi: 10.1371/journal.pone.0020334
Beck P, Ihara E, Hirota S, MacDonald J, Meng D, Nanthakumar N, et al. Exploring the interplay of barrier function and leukocyte recruitment in intestinal inflammation by targeting fucosyltransferase VII and trefoil factor 3. Am J Physiol Gastrointest liver Physiol. 2010;299:G43–53.
pubmed: 20299601
pmcid: 2904110
doi: 10.1152/ajpgi.00228.2009
Madsen J, Sorensen G, Nielsen O, Tornøe I, Thim L, Fenger C, et al. A variant form of the human deleted in malignant brain tumor 1 (DMBT1) gene shows increased expression in inflammatory bowel diseases and interacts with dimeric trefoil factor 3 (TFF3). PLoS ONE. 2013;8:e64441.
pubmed: 23691218
pmcid: 3654909
doi: 10.1371/journal.pone.0064441
Meyer zum Büschenfelde D, Tauber R, Huber O. TFF3-peptide increases transepithelial resistance in epithelial cells by modulating claudin-1 and -2 expression. Peptides. 2006;27:3383–90.
pubmed: 17018241
doi: 10.1016/j.peptides.2006.08.020
Buda A, Jepson M, Pignatelli M. Regulatory function of trefoil peptides (TFF) on intestinal cell junctional complexes. Cell Commun Adhes. 2012;19:63–68.
pubmed: 23181544
doi: 10.3109/15419061.2012.748326
Aihara E, Engevik K, Montrose M. Trefoil factor peptides and gastrointestinal function. Annu Rev Physiol. 2017;79:357–80.
pubmed: 27992733
doi: 10.1146/annurev-physiol-021115-105447
Lin N, Xu L, Sun M. The protective effect of trefoil factor 3 on the intestinal tight junction barrier is mediated by toll-like receptor 2 via a PI3K/Akt dependent mechanism. Biochem. Biophys. Res Commun. 2013;440:143–9.
pubmed: 24051092
doi: 10.1016/j.bbrc.2013.09.049
Dürer U, Hartig R, Bang S, Thim L, Hoffmann W. TFF3 and EGF induce different migration patterns of intestinal epithelial cells in vitro and trigger increased internalization of E-cadherin. Cell Physiol Biochem. 2007;20:329–46.
Le J, Zhang D, Zhao Y, Qiu W, Wang P, Sun Y. ITF promotes migration of intestinal epithelial cells through crosstalk between the ERK and JAK/STAT3 pathways. Sci Rep. 2016;6:33014.
pubmed: 27616044
pmcid: 5018822
doi: 10.1038/srep33014
Podolsky D, Gerken G, Eyking A, Cario E. Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency. Gastroenterology. 2009;137:209–20.
pubmed: 19303021
doi: 10.1053/j.gastro.2009.03.007
Teng X, Xu L, Zhou P, Sun H, Sun M. Effects of trefoil peptide 3 on expression of TNF-alpha, TLR4, and NF-kappaB in trinitrobenzene sulphonic acid induced colitis mice. Inflammation. 2009;32:120–9.
pubmed: 19238529
doi: 10.1007/s10753-009-9110-x
Shi L, Zhou P, Xi J, Yu H, Zhang B. Recombinant human trefoil factor 3 ameliorates bowel injury: its anti-inflammatory effect on experimental necrotizing enterocolitis. Int J Pept. 2014;2014:634135.
pubmed: 24688551
pmcid: 3944653
doi: 10.1155/2014/634135
Zhu Y, Tan X. TFF3 modulates NF-{kappa}B and a novel negative regulatory molecule of NF-{kappa}B in intestinal epithelial cells via a mechanism distinct from TNF-{alpha}. Am J Physiol Cell Physiol. 2005;289:C1085–1093.
pubmed: 16014704
doi: 10.1152/ajpcell.00185.2005
Barrett K. A new twist on trefoils. Focus on “TFF3 modulates NF-{kappa}B and a novel regulatory molecule of NF-{kappa}B in intestinal epithelial cells via a mechanism distinct from TNF-{alpha}”. Am J Physiol Cell Physiol. 2005;289:C1069–1071.
pubmed: 16210425
doi: 10.1152/ajpcell.00340.2005
Wang Y, Liang K, Kong W. Intestinal trefoil factor 3 alleviates the intestinal barrier function through reducing the expression of TLR4 in rats with nonalcoholic steatohepatitis. Arch Med Res. 2019;50:2–9.
pubmed: 31101239
doi: 10.1016/j.arcmed.2019.03.004
Barrera G, Sanchez G, Gonzalez J. Trefoil factor 3 isolated from human breast milk downregulates cytokines (IL8 and IL6) and promotes human beta defensin (hBD2 and hBD4) expression in intestinal epithelial cells HT-29. Bosn J Basic Med Sci. 2012;12:256–64.
pubmed: 23198942
pmcid: 4362502
doi: 10.17305/bjbms.2012.2448
Barrera G, Tortolero G. Trefoil factor 3 (TFF3) from human breast milk activates PAR-2 receptors, of the intestinal epithelial cells HT-29, regulating cytokines and defensins. Bratisl Lek Listy. 2016;117:332–9.
pubmed: 27546365
Belle N, Ji Y, Herbine K, Wei Y, Park J, Zullo K, et al. TFF3 interacts with LINGO2 to regulate EGFR activation for protection against colitis and gastrointestinal helminths. Nat Commun. 2019;10:4408.
pubmed: 31562318
pmcid: 6764942
doi: 10.1038/s41467-019-12315-1
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2021;71:209–49.
Jahan R, Shah A, Kisling S, Macha M, Thayer S, Batra S, et al. Odyssey of trefoil factors in cancer: diagnostic and therapeutic implications. Biochim Biophys Acta Rev Cancer. 2020;1873:188362.
pubmed: 32298747
doi: 10.1016/j.bbcan.2020.188362
Chen R, Chiou Y, Chong Q, Poh H, Tan T, Zhang M, et al. Pharmacological inhibition of TFF3 enhances sensitivity of CMS4 colorectal carcinoma to 5-fluorouracil through inhibition of p44/42 MAPK. Int J Mol Sci. 2019;20:6215.
Lin X, Zhang H, Dai J, Zhang W, Zhang J, Xue G, et al. TFF3 Contributes to epithelial-mesenchymal transition (EMT) in papillary thyroid carcinoma cells via the MAPK/ERK signaling pathway. J Cancer. 2018;9:4430–9.
pubmed: 30519349
pmcid: 6277656
doi: 10.7150/jca.24361
Storesund T, Hayashi K, Kolltveit K, Bryne M, Schenck K. Salivary trefoil factor 3 enhances migration of oral keratinocytes. Eur J oral Sci. 2008;116:135–40.
pubmed: 18353006
doi: 10.1111/j.1600-0722.2007.00516.x
Furuta G, Turner J, Taylor C, Hershberg R, Comerford K, Narravula S, et al. Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J Exp Med. 2001;193:1027–34.
pubmed: 11342587
pmcid: 2193432
doi: 10.1084/jem.193.9.1027
Zwaini Z, Alammari D, Byrne S, Stover C. Mode of proximal tubule damage: differential cause for the release of TFF3? Front Immunol. 2016;7:122.
pubmed: 27066010
pmcid: 4812065
doi: 10.3389/fimmu.2016.00122
Hernández C, Santamatilde E, McCreath K, Cervera A, Díez I, Ortiz-Masiá D, et al. Induction of trefoil factor (TFF)1, TFF2 and TFF3 by hypoxia is mediated by hypoxia inducible factor-1: implications for gastric mucosal healing. Br J Pharmacol. 2009;156:262–72.
pubmed: 19076725
doi: 10.1111/j.1476-5381.2008.00044.x
Guleng B, Han J, Yang J, Huang Q, Huang J, Yang X, et al. TFF3 mediated induction of VEGF via hypoxia in human gastric cancer SGC-7901 cells. Mol Biol Rep. 2012;39:4127–34.
pubmed: 21769478
doi: 10.1007/s11033-011-1195-2
Sun Y, Wang L, Zhou Y, Mao X, Deng X. Human trefoil factor 3 induces the transcription of its own promoter through STAT3. Sci Rep. 2016;6:30421.
pubmed: 27453253
pmcid: 4958921
doi: 10.1038/srep30421
Pandey V, Wu Z, Zhang M, Li R, Zhang J, Zhu T, et al. Trefoil factor 3 promotes metastatic seeding and predicts poor survival outcome of patients with mammary carcinoma. Breast Cancer Res. 2014;16:429.
pubmed: 25266665
pmcid: 4303111
doi: 10.1186/s13058-014-0429-3
Pandey V, Zhang M, You M, Zhang W, Chen R, Zhang W, et al. Expression of two non-mutated genetic elements is sufficient to stimulate oncogenic transformation of human mammary epithelial cells. Cell Death Dis. 2018;9:1147.
pubmed: 30451834
pmcid: 6242831
doi: 10.1038/s41419-018-1177-6
Yuan Z, Chen D, Chen X, Yang H, Wei Y. Overexpression of trefoil factor 3 (TFF3) contributes to the malignant progression in cervical cancer cells. Cancer cell Int. 2017;17:7.
pubmed: 28070169
pmcid: 5216547
doi: 10.1186/s12935-016-0379-1
Rivat C, Christine R, Rodrigues S, Sylvie R, Bruyneel E, Erik B, et al. Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3)—and vascular endothelial growth factor-mediated cellular invasion and tumor growth. Cancer Res. 2005;65:195–202.
pubmed: 15665295
doi: 10.1158/0008-5472.195.65.1
Lobie PE, Pandey VK, Subbegowda RK, Basappa B, Dhananjaya MC, Rangappa S. Compounds useful in inhibiting human trefoil factor 3. WO2018226155. Patent. 2018 Dec 13.
Poh H, Chiou Y, Chong Q, Chen R, Rangappa K, Ma L, et al. Inhibition of TFF3 enhances sensitivity-and overcomes acquired resistance-to doxorubicin in estrogen receptor-positive mammary carcinoma. Cancers (Basel);11:1528.
Zhang M, Wang B, Chong Q, Pandey V, Guo Z, Chen R, et al. A novel small-molecule inhibitor of trefoil factor 3 (TFF3) potentiates MEK1/2 inhibition in lung adenocarcinoma. Oncogenesis. 2019;8:65.
pubmed: 31685806
pmcid: 6828705
doi: 10.1038/s41389-019-0173-8
Hoffmann W, Jagla W, Wiede A. Molecular medicine of TFF-peptides: from gut to brain. Histol Histopathol. 2001;16:319–34.
pubmed: 11193208
Matsuoka Y, Pascall J, Brown K. Quantitative analysis reveals differential expression of mucin (MUC2) and intestinal trefoil factor mRNAs along the longitudinal axis of rat intestine. Biochim Biophys Acta. 1999;1489:336–44.
pubmed: 10673034
doi: 10.1016/S0167-4781(99)00186-4
Kobayashi K, Ogata H, Morikawa M, Iijima S, Harada N, Yoshida T, et al. Distribution and partial characterisation of IgG Fc binding protein in various mucin producing cells and body fluids. Gut. 2002;51:169–76.
pubmed: 12117874
pmcid: 1773314
doi: 10.1136/gut.51.2.169
Albert T, Laubinger W, Müller S, Hanisch F, Kalinski T, Meyer F, et al. Human intestinal TFF3 forms disulfide-linked heteromers with the mucus-associated FCGBP protein and is released by hydrogen sulfide. J Proteome Res. 2010;9:3108–17.
pubmed: 20423149
doi: 10.1021/pr100020c
Houben T, Harder S, Schlüter H, Kalbacher H, Hoffmann W. Different forms of TFF3 in the human saliva: heterodimerization with IgG Fc binding protein (FCGBP). Int J Mol Sci. 2019;20:5000.
Hoffmann W. Trefoil factor family (TFF) peptides and their diverse molecular functions in mucus barrier protection and more: changing the paradigm. Int J Mol Sci. 2020;21:4535.
Fosslien E. Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann Clin Lab Sci. 2001;31:325–48.
pubmed: 11688844
Fukuda R, Kelly B, Semenza G. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res. 2003;63:2330–4.
pubmed: 12727858
Emami S, Le Floch N, Bruyneel E, Thim L, May F, Westley B, et al. Induction of scattering and cellular invasion by trefoil peptides in src- and RhoA-transformed kidney and colonic epithelial cells. FASEB J. 2001;15:351–61.
pubmed: 11156951
doi: 10.1096/fj.00-0355com
Rodrigues S, Nguyen Q, Faivre S, Bruyneel E, Thim L, Westley B, et al. Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase- and thromboxane A2 receptor-dependent signaling pathways. FASEB J. 2001;15:1517–28.
pubmed: 11427483
doi: 10.1096/fj.00-0802com
Loos M, De Creus A, Thim L, Remaut E, Rottiers P. Murine trefoil factor 3 does not directly modulate LPS-mediated dendritic cell function. Scand J Immunol. 2007;66:35–42.
pubmed: 17587344
doi: 10.1111/j.1365-3083.2007.01944.x
Tan X, Chen Y, Liu Q, Gonzalez-Crussi F, Liu X. Prostanoids mediate the protective effect of trefoil factor 3 in oxidant-induced intestinal epithelial cell injury: role of cyclooxygenase-2. J Cell Sci. 2000:;113:2149-55.
Décaillot F, Kazmi M, Lin Y, Ray-Saha S, Sakmar T, Sachdev P. CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. J Biol Chem. 2011;286:32188–97.
pubmed: 21730065
pmcid: 3173186
doi: 10.1074/jbc.M111.277038
Dieckow J, Brandt W, Hattermann K, Schob S, Schulze U, Mentlein R, et al. CXCR4 and CXCR7 mediate TFF3-induced cell migration independently from the ERK1/2 signaling pathway. Invest Ophthalmol Vis Sci. 2016;57:56–65.
pubmed: 26780310
doi: 10.1167/iovs.15-18129
Liu D, el-Hariry I, Karayiannakis A, Wilding J, Chinery R, Kmiot W, et al. Phosphorylation of beta-catenin and epidermal growth factor receptor by intestinal trefoil factor. Lab Invest. 1997;77:557–63.
pubmed: 9426392
Baus-Loncar M, Giraud A. Multiple regulatory pathways for trefoil factor (TFF) genes. Cell Mol life Sci. 2005;62:2921–31.
pubmed: 16374580
doi: 10.1007/s00018-005-5480-x
LeSimple P, van Seuningen I, Buisine M, Copin M, Hinz M, Hoffmann W, et al. Trefoil factor family 3 peptide promotes human airway epithelial ciliated cell differentiation. Am J Respir Cell Mol Biol. 2007;36:296–303.
pubmed: 17008636
doi: 10.1165/rcmb.2006-0270OC
Fueger P, Schisler J, Lu D, Babu D, Mirmira R, Newgard C, et al. Trefoil factor 3 stimulates human and rodent pancreatic islet beta-cell replication with retention of function. Mol Endocrinol (Baltim, Md). 2008;22:1251–9.
doi: 10.1210/me.2007-0500
Williams A, Jacobs S, Moreno-Macías H, Huerta-Chagoya A, Churchhouse C, Márquez-Luna C, et al. Sequence variants in SLC16A11 are a common risk factor for type 2 diabetes in Mexico. Nature. 2014;506:97–101.
pubmed: 24390345
doi: 10.1038/nature12828
Locke A, Kahali B, Berndt S, Justice A, Pers T, Day F, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518:197–206.
pubmed: 25673413
pmcid: 4382211
doi: 10.1038/nature14177
Shungin D, Winkler T, Croteau-Chonka D, Ferreira T, Locke A, Mägi R, et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature. 2015;518:187–96.
pubmed: 25673412
pmcid: 4338562
doi: 10.1038/nature14132
Su T, Ren Q, Lu Y, Tai W, Zhu Y, Li Z, et al. A genetic variant in LINGO2 contributes to the risk of gestational diabetes mellitus in a Chinese population. J Cell Physiol. 2019;234:7012–8.
pubmed: 30426492
doi: 10.1002/jcp.27454
Jo J, Park S, Park S, Lee H, Kim C, Jung D, et al. Novel gastric cancer stem cell-related marker LINGO2 is associated with cancer cell phenotype and patient outcome. Int J Mol Sci. 2019;20:555.
Mahmood A, Melley L, Fitzgerald A, Ghosh S, Playford R. Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis. Alimentary Pharmacol Ther. 2005;21:1357–64.
doi: 10.1111/j.1365-2036.2005.02436.x
Vandenbroucke K, Hans W, Van Huysse J, Neirynck S, Demetter P, Remaut E, et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology. 2004;127:502–13.
pubmed: 15300583
doi: 10.1053/j.gastro.2004.05.020
Peterson D, Barker N, Akhmadullina L, Rodionova I, Sherman N, Davidenko I, et al. Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. J Clin Oncol. 2009;27:4333–8.
pubmed: 19636011
doi: 10.1200/JCO.2008.21.2381
Schulze U, Sel S, Paulsen F. Trefoil factor family peptide 3 at the ocular surface. A promising therapeutic candidate for patients with dry eye syndrome? Dev Ophthalmol. 2010;45:1–11.
pubmed: 20502021
doi: 10.1159/000315014
Choudhary A, Smitha C, Suresh D. Trefoils: an unexplored natural protective shield of oral cavity. J Oral Biol Craniofacial Res. 2015;5:226–31.
doi: 10.1016/j.jobcr.2015.06.009
dos Santos Silva E, Ulrich M, Döring G, Botzenhart K, Gött P. Trefoil factor family domain peptides in the human respiratory tract. J Pathol. 2000;190:133–42.
pubmed: 10657010
doi: 10.1002/(SICI)1096-9896(200002)190:2<133::AID-PATH518>3.0.CO;2-B
Schulze U, Hampel U, Sel S, Contreras-Ruiz L, Schicht M, Dieckow J, et al. Trefoil factor family peptide 3 (TFF3) is upregulated under experimental conditions similar to dry eye disease and supports corneal wound healing effects in vitro. Invest Ophthalmol Vis Sci. 2014;55:3037–42.
pubmed: 24713479
doi: 10.1167/iovs.13-13423
Madsen J, Nielsen O, Tornøe I, Thim L, Holmskov U. Tissue localization of human trefoil factors 1, 2, and 3. J Histochem Cytochem. 2007;55:505–13.
pubmed: 17242463
doi: 10.1369/jhc.6A7100.2007
Paulsen F, Varoga D, Paulsen A, Tsokos M. Trefoil factor family (TFF) peptides of normal human Vater’s ampulla. Cell Tissue Res. 2005;321:67–74.
pubmed: 15909165
doi: 10.1007/s00441-005-1131-7
Jagla W, Wiede A, Hinz M, Dietzmann K, Gülicher D, Gerlach K, et al. Secretion of TFF-peptides by human salivary glands. Cell tissue Res. 1999;298:161–6.
pubmed: 10555550
doi: 10.1007/s004419900087
Wiede A, Hinz M, Canzler E, Franke K, Quednow C, Hoffmann W. Synthesis and localization of the mucin-associated TFF-peptides in the human uterus. Cell Tissue Res. 2001;303:109–15.
pubmed: 11235998
doi: 10.1007/s004410000297
Vestergaard E, Nexo E, Wendt A, Guthmann F. Trefoil factors in human milk. Early Hum Dev. 2008;84:631–5.
pubmed: 18502057
doi: 10.1016/j.earlhumdev.2008.04.001
Langer G, Walter S, Behrens-Baumann W, Hoffmann W. [TFF peptides. New mucus-associated secretory products of the conjunctiva]. Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2001;98:976–9..
Paulsen F, Hinz M, Schaudig U, Thale A, Hoffmann W. TFF peptides in the human efferent tear ducts. Invest Ophthalmol Vis Sci. 2002;43:3359–64.
pubmed: 12407144
Steven P, Schäfer G, Nölle B, Hinz M, Hoffmann W, Paulsen F. Distribution of TFF peptides in corneal disease and pterygium. Peptides. 2004;25:819–25.
pubmed: 15177877
doi: 10.1016/j.peptides.2004.01.023
Taupin D, Kinoshita K, Podolsky D. Intestinal trefoil factor confers colonic epithelial resistance to apoptosis. Proc Natl Acad Sci USA. 2000;97:799–804.
pubmed: 10639160
pmcid: 15411
doi: 10.1073/pnas.97.2.799
Fu T, Znalesniak E, Kalinski T, Möhle L, Biswas A, Salm F, et al. TFF peptides play a role in the immune response following oral infection of mice with toxoplasma gondii. Eur J Microbiol Immunol. 2015;5:221–31.
doi: 10.1556/1886.2015.00028
Taupin D, Wu D, Jeon W, Devaney K, Wang T, Podolsky D. The trefoil gene family are coordinately expressed immediate-early genes: EGF receptor- and MAP kinase-dependent interregulation. J Clin Invest. 1999;103:R31–38.
pubmed: 10225980
pmcid: 408349
doi: 10.1172/JCI3304
Yu K, Jiang S, Lin M, Wu J, Lin J. Extraction and purification of biologically active intestinal trefoil factor from human meconium. Lab Invest. 2004;84:390–2.
pubmed: 14767484
doi: 10.1038/labinvest.3700042
Kjellev S, Nexø E, Thim L, Poulsen S. Systemically administered trefoil factors are secreted into the gastric lumen and increase the viscosity of gastric contents. Br J Pharmacol. 2006;149:92–99.
pubmed: 16880764
pmcid: 1629411
doi: 10.1038/sj.bjp.0706840
Zhang B, Yu H, Sheng Z, Luo H, Yu J. The therapeutic effect of recombinant human trefoil factor 3 on hypoxia-induced necrotizing enterocolitis in immature rat. Regulatory Pept. 2003;116:53–60.
doi: 10.1016/S0167-0115(03)00177-0
Kjellev S, Thim L, Pyke C, Poulsen S. Cellular localization, binding sites, and pharmacologic effects of TFF3 in experimental colitis in mice. Digestive Dis Sci. 2007;52:1050–9.
doi: 10.1007/s10620-006-9256-4
Limaye S, Haddad R, Cilli F, Sonis S, Colevas A, Brennan M, et al. Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer. 2013;119:4268–76.
pubmed: 24114811
doi: 10.1002/cncr.28365